Zhejiang Shapuaisi Pharmaceutical Co. Ltd. (603168) Stock Analysis

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Poor Management Efficiency with a low ROCE of 1.63%

The company has been able to generate a Return on Capital Employed (avg) of 1.63% signifying low profitability per unit of total capital (equity and debt)

Poor long term growth as Net Sales has grown by an annual rate of 4.43% and Operating profit at 10.09% over the last 5 years

The company has declared Negative results for the last 6 consecutive quarters

Risky -

Underperformed the market in the last 1 year

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CNY 2,334 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.05

Return on Equity

-3.38%

Price to Book

1.45

Revenue and Profits:

Net Sales:

132 Million

(Quarterly Results - Jun 2025)

Net Profit:

13 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-0.48%

6 Months

8.12%

1 Year

0.98%

2 Years

-22.15%

3 Years

-5.49%

4 Years

-5.06%

5 Years

4.96%

Zhejiang Shapuaisi Pharmaceutical Co. Ltd. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Zhejiang Shapuaisi Pharmaceutical Co. Ltd. Reports Strong Financial Performance in Q1 2025

Zhejiang Shapuaisi Pharmaceutical Co. Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reported impressive financial results for the quarter ending March 2025. The company has demonstrated significant growth, showcasing its potential for future profitability and resilience in the market.

One of the key highlights of the financial performance is the substantial decrease in raw material costs, which fell by 24.65% year-over-year. This reduction has positively impacted the company's overall profitability, allowing it to achieve its highest pre-tax profit of CNY 14.03 MM for the quarter.

In addition to the pre-tax profit, Zhejiang Shapuaisi Pharmaceutical Co. Ltd. recorded a net profit of CNY 11.83 MM, marking another peak in its financial journey. The earnings per share (EPS) also reached a high of CNY 0.02, reflecting the company'...

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

4.43%

EBIT Growth (5y)

10.09%

EBIT to Interest (avg)

-18.09

Debt to EBITDA (avg)

Net Debt to Equity (avg)

0.04

Sales to Capital Employed (avg)

0.29

Tax Ratio

4.10%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

1.63%

ROE (avg)

1.42%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.45

EV to EBIT

-59.82

EV to EBITDA

71.62

EV to Capital Employed

1.43

EV to Sales

5.07

PEG Ratio

Dividend Yield

ROCE (Latest)

-2.38%

ROE (Latest)

-3.38%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Mildly Bullish

Dow Theory

Mildly Bullish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 32.04% vs -18.27% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 47.73% vs 109.45% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "132.30",
          "val2": "100.20",
          "chgp": "32.04%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "44.80",
          "val2": "21.00",
          "chgp": "113.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.40",
          "val2": "1.90",
          "chgp": "26.32%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-5.60",
          "val2": "-3.00",
          "chgp": "-86.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "13.00",
          "val2": "8.80",
          "chgp": "47.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "206.50%",
          "val2": "35.40%",
          "chgp": "17.11%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -25.03% vs 17.16% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -584.06% vs -43.97% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "477.50",
          "val2": "636.90",
          "chgp": "-25.03%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "15.90",
          "val2": "95.60",
          "chgp": "-83.37%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "8.50",
          "val2": "6.00",
          "chgp": "41.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-45.10",
          "val2": "-0.20",
          "chgp": "-22,450.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-121.50",
          "val2": "25.10",
          "chgp": "-584.06%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-121.60%",
          "val2": "32.40%",
          "chgp": "-15.40%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

132.30

100.20

32.04%

Operating Profit (PBDIT) excl Other Income

44.80

21.00

113.33%

Interest

2.40

1.90

26.32%

Exceptional Items

-5.60

-3.00

-86.67%

Consolidate Net Profit

13.00

8.80

47.73%

Operating Profit Margin (Excl OI)

206.50%

35.40%

17.11%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 32.04% vs -18.27% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 47.73% vs 109.45% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

477.50

636.90

-25.03%

Operating Profit (PBDIT) excl Other Income

15.90

95.60

-83.37%

Interest

8.50

6.00

41.67%

Exceptional Items

-45.10

-0.20

-22,450.00%

Consolidate Net Profit

-121.50

25.10

-584.06%

Operating Profit Margin (Excl OI)

-121.60%

32.40%

-15.40%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -25.03% vs 17.16% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -584.06% vs -43.97% in Dec 2023

All Annual Results

Company CV

About Zhejiang Shapuaisi Pharmaceutical Co. Ltd.

Zhejiang Shapuaisi Pharmaceutical Co. Ltd.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Zhejiang Shapuaisi Pharmaceutical Co. Ltd.

1Day

52 Week

CASH

FII

DII

Promoter

MarketsMojo — Loved in India, Now Global

Dashboard

Poor Management Efficiency with a low ROCE of 1.63%

Poor long term growth as Net Sales has grown by an annual rate of 4.43% and Operating profit at 10.09% over the last 5 years

The company has declared Negative results for the last 6 consecutive quarters

Risky -

Underperformed the market in the last 1 year

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Zhejiang Shapuaisi Pharmaceutical Co. Ltd. Reports Strong Financial Performance in Q1 2025

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Zhejiang Shapuaisi Pharmaceutical Co. Ltd.

Company Coordinates